Framing an intervention as focused on one's strength: Does framing enhance therapeutic benefit?

Once recombinant human erythropoietin (r-HuEPO) was introduced in daily practice, huge steps were made in combating the adverse effects induced by anemia in chronic kidney disease population. Still, r-HuEPO resistance and the doses ensuring the maximum therapeutic benefit remain matters of debate. The aim of our study was to assess the correlation between the presence and the degree of inflammation and the r-HuEPO requirements in chronic dialysis patients. We conducted a 2 years prospective study on 146 patients undergoing chronic dialysis treated with r-HuEPO. Based on their average CRP (C-reactive protein) levels, obtained from repeated samplings at 3 months interval, 3 groups were formed; we noted in each group the average values of r-HuEPO prescribed to achieve the optimum hemoglobin levels according to the dialysis best practice guidelines and all the adverse effects of the therapy. A direct correlation was observed between CRP levels and r-HuEPO requirements in the first 2 groups of patients (CRP under 6 mg/L and CRP values 6-20 mg/L), with significant increase in r-HuEPO doses between groups (p [ 0.001); the third group, CRP values over 20 mg/dL, showed a minor, insignificant increase in average r-HuEPO doses compared to mild inflammation group (p = 0.199) and more adverse effects of the therapy (p [ 0.05). Inflammation is an important determinant of anemia in chronic dialysis patients and can induce an increase in the doses of r-HuEPO. However, prescribing excessive r-HuEPO doses is not the answer in severe inflammatory status, due to lack of response and possible adverse effects.

Download Full-text

EXPERIMENTAL STUDY OF THE EFFICACY OF L-LYSINE-A-OXIDASE TRICHODERMA CF. AUREOVIRIDE RIFAI ON MODELS OF XENOGRAFTS OF HUMAN TUMORS IN ATHYMIC MICE AND EVALUATION OF SYNERGISM WITH CISPLATIN OR TOPOISOMERASE INHIBITORS

Problems in oncology ◽

10.37469/0507-3758-2017-63-3-497-505 ◽

2017 ◽

Vol 63 (3) ◽

pp. 497-505

Author(s):

Vadim Pokrovskiy ◽

Yelena Lukasheva ◽

Nikolay Chernov ◽

Yelena Treshchalina

Keyword(s):

Experimental Study ◽

Life Expectancy ◽

Therapeutic Benefit ◽

Human Tumors ◽

Lymphocytic Leukemia ◽

Antitumor Drugs ◽

Athymic Mice ◽

Lewis Lung ◽

Topoisomerase Inhibitors ◽

Inhibition Of Growth

The effectiveness of L-lysine-alpha oxidase Trichoderma cf. Aureoviride Rifai BKMF-4268D (LO) on models of subcutaneous xenografts of human tumors in athymic mice as well as the effectiveness of combination therapy with known antitumor drugs: cisplatin, irinotecan, etoposide on models of P388 lymphocytic leukemia, Lewis lung (LLC) and B16 melanoma was evaluated. The intraperitoneal injection of LO in a discrete regime at doses of 150-75-75-75-75 E/kg demonstrated inhibition of growth of all studied xenografts of human tumors in athymic mice. The combination of irinotecan+LO on the LLC model gave a significant summative therapeutic benefit with an increase in mouse life expectancy up to 35%. Cisplatin and LO realized a significant (p

Download Full-text

The Therapeutic Benefit of Radiotherapy for Chordoma Patients with Positive Surgical Margins

SSRN Electronic Journal ◽

10.2139/ssrn.3420424 ◽

2019 ◽

Author(s):

Brian L. Dial ◽

David L. Kerr ◽

Alexander L. Lazarides ◽

Anthony A. Catanzano ◽

Cindy L. Green ◽

...

Keyword(s):

Therapeutic Benefit ◽

Surgical Margins ◽

Positive Surgical Margins

Download Full-text

Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy

Current Pharmaceutical Design ◽

10.2174/1381612822666161026162347 ◽

2017 ◽

Vol 23 (3) ◽

pp. 454-466 ◽

Cited By ~ 16

Author(s):

Daniele R. Nogueira-Librelotto ◽

Cristiane F. Codevilla ◽

Ammad Farooqi ◽

Clarice M. B. Rolim

Keyword(s):

Drug Delivery ◽

Cancer Therapy ◽

Tumor Cells ◽

Therapeutic Benefit ◽

Active Targeting ◽

Future Research ◽

Passive Targeting ◽

The Right ◽

Review Current ◽

Target Effects

A lot of effort has been devoted to achieving active targeting for cancer therapy in order to reach the right cells. Hence, increasingly it is being realized that active-targeted nanocarriers notably reduce off-target effects, mainly because of targeted localization in tumors and active cellular uptake. In this context, by taking advantage of the overexpression of transferrin receptors on the surface of tumor cells, transferrin-conjugated nanodevices have been designed, in hope that the biomarker grafting would help to maximize the therapeutic benefit and to minimize the side effects. Notably, active targeting nanoparticles have shown improved therapeutic performances in different tumor models as compared to their passive targeting counterparts. In this review, current development of nano-based devices conjugated with transferrin for active tumor-targeting drug delivery are highlighted and discussed. The main objective of this review is to provide a summary of the vast types of nanomaterials that have been used to deliver different chemotherapeutics into tumor cells, and to ultimately evaluate the progression on the strategies for cancer therapy in view of the future research.

Download Full-text